160 related articles for article (PubMed ID: 9672235)
21. Improving HIV-specific immune responses in HIV-infected patients.
Hardy GA; Imami N; Gotch FM
J HIV Ther; 2002 May; 7(2):40-5. PubMed ID: 12553687
[TBL] [Abstract][Full Text] [Related]
22. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.
Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B
J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897
[TBL] [Abstract][Full Text] [Related]
23. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
[TBL] [Abstract][Full Text] [Related]
24. Immune Response and NIH begin pediatric clinical trial of Remune HIV therapy. National Institutes of Health.
J Int Assoc Physicians AIDS Care; 1996 Jul; 2(7):44. PubMed ID: 11363748
[TBL] [Abstract][Full Text] [Related]
25. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.
Markowitz M; Jin X; Hurley A; Simon V; Ramratnam B; Louie M; Deschenes GR; Ramanathan M; Barsoum S; Vanderhoeven J; He T; Chung C; Murray J; Perelson AS; Zhang L; Ho DD
J Infect Dis; 2002 Sep; 186(5):634-43. PubMed ID: 12195350
[TBL] [Abstract][Full Text] [Related]
26. Clinical trials of HIV treatment begin in Thailand.
AIDS Wkly Plus; 1996 Apr 8-15; ():14. PubMed ID: 12320053
[TBL] [Abstract][Full Text] [Related]
27. Immune-based therapy shows promise.
AIDS Patient Care STDS; 2005 Jun; 19(6):415. PubMed ID: 16041868
[No Abstract] [Full Text] [Related]
28. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.
Ratto-Kim S; Garner RP; Kim JH; Jagodzinski LL; Michael NL; Paris R; Redfield RR; Birx DL
J Infect Dis; 2004 Jun; 189(11):1988-95. PubMed ID: 15143464
[TBL] [Abstract][Full Text] [Related]
29. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
[TBL] [Abstract][Full Text] [Related]
30. Agouron and immune response to commercialize remune immune-based treatment.
James JS
AIDS Treat News; 1998 Jun; (No 297):1. PubMed ID: 11365593
[TBL] [Abstract][Full Text] [Related]
31. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic analysis of human immunodeficiency virus (HIV) type 1 cell-mediated immune responses after treatment with an HIV-1 immunogen.
Moss RB; Wallace MR; Giermakowska WK; Webb E; Savary J; Chamberlin-Brandt C; Theofan G; Musil R; Richieri SP; Jensen FC; Carlo DJ
J Infect Dis; 1999 Sep; 180(3):641-8. PubMed ID: 10438350
[TBL] [Abstract][Full Text] [Related]
33. Correlation between the degree of immune activation, production of IL-2 and FOXP3 expression in CD4+CD25+ T regulatory cells in HIV-1 infected persons under HAART.
Terzieva V; Popova D; Kicheva M; Todorova Y; Markova R; Martinova F; Elenkov I; Yankova M
Int Immunopharmacol; 2009 Jul; 9(7-8):831-6. PubMed ID: 19303058
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy.
Sukeepaisarncharoen W; Churdboonchart V; Kulpradist S; Isarangkura Na Ayudthya B; Rugpao S; Chandeying V; Sirawaraporn W; Carlo D; Moss RB
HIV Clin Trials; 2001; 2(5):391-8. PubMed ID: 11673813
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic immunization strategies for the control of HIV-1.
Dorrell L
Expert Rev Vaccines; 2005 Aug; 4(4):513-20. PubMed ID: 16117708
[TBL] [Abstract][Full Text] [Related]
36. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
[TBL] [Abstract][Full Text] [Related]
37. Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.
Sereti I; Lane HC
Clin Infect Dis; 2001 Jun; 32(12):1738-55. PubMed ID: 11360217
[TBL] [Abstract][Full Text] [Related]
38. Vaccines for HIV--Remune returns.
TreatmentUpdate; 2004 Oct; 16(6):3. PubMed ID: 17219678
[No Abstract] [Full Text] [Related]
39. Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection.
Jones T
Curr Opin Investig Drugs; 2010 Aug; 11(8):964-70. PubMed ID: 20721838
[TBL] [Abstract][Full Text] [Related]
40. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs.
Turner JL; Kostman JR; Aquino A; Wright D; Szabo S; Bidwell R; Goodgame J; Daigle A; Kelley E; Jensen F; Duffy C; Carlo D; Moss RB
HIV Med; 2001 Apr; 2(2):68-77. PubMed ID: 11737381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
